AR101742A1 - Agonista del receptor de calcitonina y amilina - Google Patents
Agonista del receptor de calcitonina y amilinaInfo
- Publication number
- AR101742A1 AR101742A1 ARP150102805A ARP150102805A AR101742A1 AR 101742 A1 AR101742 A1 AR 101742A1 AR P150102805 A ARP150102805 A AR P150102805A AR P150102805 A ARP150102805 A AR P150102805A AR 101742 A1 AR101742 A1 AR 101742A1
- Authority
- AR
- Argentina
- Prior art keywords
- amiline
- calcitonine
- derivatives
- receiver agonist
- agonist
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- BBBFJLBPOGFECG-UHFFFAOYSA-N salmon calcitonin Chemical compound C=1N=CNC=1CC(C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)NC(CC=1C=CC(O)=CC=1)C(=O)N1C(CCC1)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N1C(CCC1)C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1 BBBFJLBPOGFECG-UHFFFAOYSA-N 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14183551 | 2014-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101742A1 true AR101742A1 (es) | 2017-01-11 |
Family
ID=51483301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102805A AR101742A1 (es) | 2014-09-04 | 2015-09-02 | Agonista del receptor de calcitonina y amilina |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9593149B2 (enExample) |
| EP (1) | EP3189071B1 (enExample) |
| JP (3) | JP6728141B2 (enExample) |
| CN (1) | CN106687474A (enExample) |
| AR (1) | AR101742A1 (enExample) |
| ES (1) | ES2887370T3 (enExample) |
| TW (1) | TW201625671A (enExample) |
| WO (1) | WO2016034604A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6769984B2 (ja) | 2015-03-18 | 2020-10-14 | ジーランド ファーマ アクティーゼルスカブ | アミリン類似体 |
| US10071140B2 (en) | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
| JP7076442B2 (ja) | 2016-11-07 | 2022-05-27 | ノヴォ ノルディスク アー／エス | Ｐｅｇ化合物のｄｃｈｂｓ活性エステル及びその使用 |
| CN109248323B (zh) * | 2017-07-14 | 2023-09-08 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| US11274158B2 (en) | 2018-01-30 | 2022-03-15 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators |
| CN113195524A (zh) | 2018-10-11 | 2021-07-30 | 因塔西亚治疗公司 | 人类胰淀素类似物多肽和使用方法 |
| CN110467666A (zh) * | 2019-09-17 | 2019-11-19 | 湖北强耀生物科技有限公司 | 一种新型胰岛淀粉样多肽的合成方法 |
| AR124295A1 (es) | 2020-12-18 | 2023-03-15 | Lilly Co Eli | Agonistas duales del receptor de amilina y calcitonina y usos de los mismos |
| TWI850611B (zh) | 2020-12-18 | 2024-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
| WO2022248419A2 (en) | 2021-05-22 | 2022-12-01 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4144362A1 (en) | 2021-09-06 | 2023-03-08 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4129324A1 (en) | 2021-08-02 | 2023-02-08 | Adocia | Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist |
| AU2022386166A1 (en) | 2021-11-10 | 2024-06-20 | I2O Therapeutics, Inc. | Ionic liquid compositions |
| CN116621944A (zh) * | 2022-02-10 | 2023-08-22 | 成都奥达生物科技有限公司 | 一种长效肝炎病毒进入抑制剂 |
| CN120112280A (zh) | 2022-08-29 | 2025-06-06 | 伊莱利利公司 | 用于口服递送的组合物 |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| WO2025114501A1 (en) | 2023-11-30 | 2025-06-05 | Novo Nordisk A/S | Tri-agonists of the glp-1, gip, and amylin receptors |
| WO2025240893A1 (en) | 2024-05-17 | 2025-11-20 | Eli Lilly And Company | 4-phenyl-1h-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives as amylin and/or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4414149A (en) | 1983-03-04 | 1983-11-08 | Armour Pharmaceutical Company | Glycine8 -D-arginine24 calcitonin |
| US4495097A (en) | 1983-04-04 | 1985-01-22 | Armour Pharmaceutical Company | Des-serine2 -glycine8 calcitonin |
| US4659804A (en) | 1984-11-01 | 1987-04-21 | Armour Pharmaceutical Company | (Bis-1,7-S-acetamidomethyl-L-cysteine)salmon calcitonin |
| US4622386A (en) * | 1985-03-28 | 1986-11-11 | Armour Pharmaceutical Company | [1,7-di-alanine]calcitonin |
| EP0297159A1 (en) * | 1987-07-01 | 1989-01-04 | Armour Pharmaceutical Company | [N-Acyl, 1,7-Di-Aline] calcitonins, method for their preparation, pharmaceutical compositions and use |
| AU629552B2 (en) | 1988-06-16 | 1992-10-08 | Teijin Limited | S-sulfonated calcitonin derivatives |
| US6143718A (en) * | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
| CN1064051C (zh) | 1997-04-30 | 2001-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 不含二硫键的鲑鱼和鳗鱼降钙素类似物及其制备方法 |
| US6087334A (en) * | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| US8076288B2 (en) * | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| WO2007014051A2 (en) | 2005-07-22 | 2007-02-01 | Amylin Pharmaceuticals, Inc. | Use of amylin and amylin agonists as cardioprotective or myoprotective agents |
| EP2293811A1 (en) * | 2008-06-25 | 2011-03-16 | Novo Nordisk A/S | Derivatised hybrid peptides of amylin and salmon calcitonin |
| CA2750035C (en) * | 2009-01-22 | 2018-02-27 | Unigene Laboratories Inc. | Treatment for obesity |
| KR101673042B1 (ko) | 2009-03-12 | 2016-11-04 | 키바이오사이언스 아게 | 당뇨병 및 대사 증후군의 치료 |
| MX351128B (es) * | 2010-09-28 | 2017-10-03 | Aegerion Pharmaceuticals Inc | Polipeptidos manipulados que tienen duracion de accion incrementada. |
| CN103826655A (zh) * | 2011-05-25 | 2014-05-28 | 安米林药品有限责任公司 | 胰岛淀粉样多肽及其衍生物和用途 |
| WO2012168430A2 (en) * | 2011-06-10 | 2012-12-13 | Novo Nordisk A/S | Polypeptides |
-
2015
- 2015-09-02 TW TW104128938A patent/TW201625671A/zh unknown
- 2015-09-02 WO PCT/EP2015/069996 patent/WO2016034604A1/en not_active Ceased
- 2015-09-02 EP EP15766071.3A patent/EP3189071B1/en active Active
- 2015-09-02 CN CN201580046850.8A patent/CN106687474A/zh active Pending
- 2015-09-02 JP JP2017512822A patent/JP6728141B2/ja active Active
- 2015-09-02 ES ES15766071T patent/ES2887370T3/es active Active
- 2015-09-02 AR ARP150102805A patent/AR101742A1/es unknown
-
2016
- 2016-05-10 US US15/151,093 patent/US9593149B2/en active Active
-
2017
- 2017-01-27 US US15/417,671 patent/US10174082B2/en active Active
-
2020
- 2020-07-01 JP JP2020114038A patent/JP7095027B2/ja active Active
-
2022
- 2022-06-22 JP JP2022100480A patent/JP2022130522A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2887370T3 (es) | 2021-12-22 |
| US20160272683A1 (en) | 2016-09-22 |
| EP3189071A1 (en) | 2017-07-12 |
| EP3189071B1 (en) | 2021-07-28 |
| JP2022130522A (ja) | 2022-09-06 |
| JP6728141B2 (ja) | 2020-07-22 |
| JP2017530108A (ja) | 2017-10-12 |
| JP2020169197A (ja) | 2020-10-15 |
| US20170145059A1 (en) | 2017-05-25 |
| JP7095027B2 (ja) | 2022-07-04 |
| CN106687474A (zh) | 2017-05-17 |
| TW201625671A (zh) | 2016-07-16 |
| WO2016034604A1 (en) | 2016-03-10 |
| US9593149B2 (en) | 2017-03-14 |
| US10174082B2 (en) | 2019-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101742A1 (es) | Agonista del receptor de calcitonina y amilina | |
| CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
| EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
| EA201792500A1 (ru) | Aav-опосредованная экспрессия антител против гриппа и способы их использования | |
| CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
| MX381160B (es) | Agonistas del receptor de apelina y metodos de uso. | |
| PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| EA201791117A1 (ru) | Частичные агонисты инсулинового рецептора | |
| BR112017008666A2 (pt) | anticorpos anti-fgfr2/3 e métodos de uso dos mesmos | |
| CL2015003290A1 (es) | Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4). | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| BR112016024494A8 (pt) | análogo de peptídeo e seu uso | |
| MX391306B (es) | COMPOSICIONES PARA LA LIBERACIÓN PROLONGADA DE ANTAGONISTAS DE LA HORMONA LIBERADORA DE GONADOTROPINA (GnRH) | |
| CR20160002A (es) | Formulación estable líquida de etelcalcetide (amg 461) | |
| BR112018002983A2 (pt) | composição compreendendo uma lactama e um álcool | |
| BR112017003219A2 (pt) | formulação de acetato de abiraterona e métodos de uso | |
| MX389026B (es) | Una composicion farmaceutica y el uso de la misma. | |
| CL2019002733A1 (es) | Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico. | |
| MX2017000862A (es) | Formulacion de factor viii. | |
| BR112016027133A8 (pt) | derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| MX373197B (es) | Formulaciones estables de undecanoato de testosterona. | |
| CY1123219T1 (el) | Βελτιωμενα αντισωματα αλφα v βητα 8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |